Similarly, adenoviral vectors have been used to mediate gene editing targeting Pten in a mouse model of nonalcoholic steatohepatitis (NASH), in which mice injected with adenoviral vector show signs of hepatomegaly and NASH after 4 months. This evidence concerns the gene PTEN and metabolic dysfunction-associated steatohepatitis.